Malignant gliomas: old and new systemic treatment approaches

by Mesti Tanja, Ocvirk Janja
Published 2016-06-01

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of...

by Hlebanja Zvezdana, Rebersek Martina, Skof Erik, Ocvirk Janja
Published 2009-04-01

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients

by Rebersek Martina, Mesti Tanja, Boc Marko, Ocvirk Janja
Published 2019-03-01

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib

by Gavric Ana Ursula, Ocvirk Janja, Mekjavic Polona Jaki
Published 2018-01-01

Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis

by Jagric Tomaz, Ilijevec Bojan, Velenik Vaneja, Ocvirk Janja, Potrc Stojan
Published 2019-05-01

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes

by Mesti Tanja, Ceplak Mencin Vid, Mileva Boshkoska Biljana, Ocvirk Janja
Published 2021-05-01

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

by Mesti Tanja, Ebert Moltara Maja, Boc Marko, Rebersek Martina, Ocvirk Janja
Published 2015-03-01

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement

by Mesti Tanja, Boshkoska Biljana Mileva, Kos Mitja, Tekavčič Metka, Ocvirk Janja
Published 2015-06-01

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience

by Hribernik Nezka, Boc Marko, Ocvirk Janja, Knez-Arbeiter Jasna, Mesti Tanja, Ignjatovic Marija, Rebersek Martina
Published 2020-01-01

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma

by Moltara Maja Ebert, Novakovic Srdjan, Boc Marko, Bucic Marina, Rebersek Martina, Zadnik Vesna, Ocvirk Janja
Published 2018-04-01

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience

by Ocvirk Janja, Moltara Maja Ebert, Mesti Tanja, Boc Marko, Rebersek Martina, Volk Neva, Benedik Jernej, Hlebanja Zvezdana
Published 2016-06-01

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

by Edhemovic Ibrahim, Oblak Irena, Anderluh Franc, Bracko Matej, Music Maja, Ocvirk Janja, Velenik Vaneja, Brecelj Erik, Kropivnik Mateja, Omejc Mirko
Published 2011-08-01

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells

by Mesti Tanja, Bouchemal Nadia, Banissi Claire, Triba Mohamed N., Marbeuf-Gueye Carole, Cemazar Maja, Moyec Laurence Le, Carpentier Antoine F., Savarin Philippe, Ocvirk Janja
Published 2018-11-01